1-2 of 2
Jeremy Loyau
Close
Sort by
Journal Articles

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

Maria Pihlgren, Olivia Hall, Laura Carretero, Carole Estoppey, Adam Drake, Daniela Pais, Jeremy Loyau, Jeremy Berret, Isabelle Gruber, Perrine Suere, Vincent Schnorhk, Emilie Nallet, Blandine Pouleau, Myriam Chimen, Julie Macoin, Elodie Stainnack, Thierry Monney, Aurore Delachat, Cyrille Dreyfus, Thomas Matthes, Cyril Konto, Michael Dyson, Stanislas Blein, Lamine Mbow, Rebecca Wood, Ankita Srivastava, Eugene Zhukovsky, Mario Perro
Journal: Blood
Blood (2022) 140 (Supplement 1): 858–859.
https://doi.org/10.1182/blood-2022-159353
Published: 2022
Journal Articles

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

Sammicheli Stefano, Camille Grandclement, Elie Dehilly, Maria Panagopoulou, Evangelia Martini, Rosa Castillo, Perrine Suere, Blandine Pouleau, Carole Estoppey, Julia Frei, Jeremy Loyau, Thierry Monney, Rebecca Wood, Amelie Croset, Alain Rubod, Girish Gudi, Venkatesha Udupa, Sunitha Gn, Vinu Menon, Daniel Rasmussen, Jeppe Koch Olsen, Roberto Giovannini, Aravind Chakrapani, Stanislas Blein, Marie-Agnes Doucey, Adam Drake, Alessandro Riva, Cyril Konto, Mario Perro, Lamine Mbow
Journal: Blood
Blood (2021) 138 (Supplement 1): 73.
https://doi.org/10.1182/blood-2021-145586
Published: 2021